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Abstract
In recent years we have performed more than 1,000 radioimmunoassays of ghrelin and obestatin. In these assays, we have encountered 
several technological obstacles. Another difficulty was the enormous discrepancy of plasma ghrelin results published by different authors. 
The aim of this article is to comment on these problems. Not all peptides of the hypothalamus and intestines are present in blood 
circulation. Several neuropeptides do not cross the blood-brain barrier, and several gastrointestinal peptides are present in extremely 
low concentrations in the blood. That requires time-consuming and laborious extraction. In these procedures, considerable amounts of 
peptides may be lost. In addition, these peptides are very unstable and prone to enzymatic degradation. This makes it mandatory to add 
enzymatic inhibitors to plasma samples. The peptides are also unstable in elevated temperatures, hence the assays should be performed 
in air-conditioned laboratories and the kits should be transported in proper low temperature conditions. Peptides may appear in several 
isoforms of different biological activity, but antibodies routinely used in these assays are polyclonal and do not differentiate between these 
forms. This complicates clinical evaluation of the results. To date, there are no international standards of ghrelin, obestatin or other active 
peptides, probably because of their extreme instability. Because of technological difficulties, the results of peptide assays performed in 
different scientific research institutions vary greatly and cannot be compared to each other. This disadvantage may be partially diminished 
by including samples of healthy subjects in each assay run to check whether the peptide concentrations of the patients differ significantly 
from that of control subjects. (Pol J Endocrinol 2011; 62 (4): 336–339)
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Streszczenie
W trakcie kilkuletnich doświadczeń wykonano ponad 1000 radioimmunologicznych oznaczeń greliny i obestatyny, przy których wyka-
zano liczne trudności techniczne. Inną trudnością była niezwykle wielka rozbieżność wyników greliny w publikacjach różnych autorów. 
Celem pracy jest omówienie tych problemów.
Tylko niektóre peptydy podwzgórza i przewodu pokarmowego są możliwe do oznaczania we krwi krążącej, bowiem część neuropeptydów 
nie przekracza bariery krew–mózg. Niektóre hormony przewodu pokarmowego występują w niezwykle małych stężeniach. Wymaga to 
wykonania żmudnych i pracochłonnych ekstraktów, w trakcie których dochodzi do strat części peptydów. Ponadto peptydy są nietrwałe 
i łatwo ulegają rozkładowi. Są one także wrażliwe na wysokie temperatury, stąd niezbędne jest zachowanie niskich temperatur otoczenia 
w trakcie wykonywania oznaczeń oraz dodawanie do osocza substancji hamujących aktywność enzymów. Peptydy mogą występować 
w postaci izoform oraz form aktywnych i nieaktywnych, co utrudnia ocenę wyników badań, bowiem obie formy mogą mieć odmienne 
działanie biologiczne. Jednak stosowane w zestawach RIA przeciwciała są poliklonalne i nie różnicują tych izoform. Brak międzynarodo-
wych standardów uniemożliwia porównywanie wyników badań różnych ośrodków naukowych. Dlatego w każdej serii oznaczeń powinna 
być dołączona grupa kontrolna osób zdrowych w celu sprawdzenia, czy wyniki stężeń peptydów osób chorych różnią się statystycznie 
od uzyskanych u osób zdrowych. (Endokrynol Pol 2011; 62 (4): 336–339)
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Introduction
Ghrelin and obestatin are derived from the same precur-
sor (preproghrelin). Ghrelin is a 28-aminoacid peptide 
discovered by Kojima et al. in 1999 [1], produced mainly 
in the X/A cells of the stomach and, to a lesser extent, by 
the intestines, pancreas, hypothalamus and pituitary. 
Initial studies in rodents [2] followed by studies in hu-
mans revealed that ghrelin stimulates GH, ACTH and 
prolactin release, increases appetite and food uptake 
[4, 5] by acting on the hypothalamus arcuate nucleus 
and increasing secretion of neuropeptide Y (NPY) and 
agouti-related peptide (AgRP). In humans, Cummings 
studied ghrelin secretion in physiological conditions 
and presented detailed results of 24-hour ghrelin secre-
tion profile; ghrelin level increased before meals and 
decreased rapidly after meals [6]. 
Preproghrelin also encodes another 23-amino acid 
peptide discovered by Zhang et al. in 2005 [7]. This 
ghrelin-associated peptide was named obestatin, imply-
ing its anti-obesity action. In their study, this peptide 
decreased appetite, food intake and body mass in 
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rodents, thus suggesting its antagonistic effects to the 
well-known properties of ghrelin. The scientists hoped 
for a breakthrough in the treatment of obesity, but other 
authors were unable to confirm these observations as 
they failed to find alterations in feeding behaviour in 
either rodents or humans [8–12]. Scientific opinion still 
differs as to whether obestatin is biologically active or 
just an inactive accessory peptide fragment originated 
during ghrelin processing.
Not only ghrelin, but also agouti-related protein 
(AgRP) and neuropeptide Y (NPY), belong to the 
appetite-stimulatory peptides. Their main activity is 
restricted to hypothalamic neurons and ghrelin-pro-
ducing gastric X/A cells. These peptides do not cross 
the blood-brain barrier, hence mechanisms and effects 
of these peptides can be analysed only in experimental 
studies in rodents or by immunohistochemical and 
in-situ hybrydisation of the hypothalamus. 
In addition, the activity of these peptides may be 
observed after intraventricular injections of ghrelin 
or obestatin and studies of how these peptides affect 
feeding behaviour in experimental animals. AgRP 
and NPY cannot be measured in circulating blood, 
meaning that papers on NPY published 20 years ago 
are no longer valid. Moreover, since then, no further 
papers on NPY in blood have been published. Among 
appetite-stimulating peptides, only ghrelin is present in 
the circulation in quantities that allow its measurement. 
In the Department of Endocrinology in recent years 
we have performed more than 1,000 ghrelin and obesta-
tin radioimmunoassays, and some results of these studies 
have been published [15–20]. In performing RIA assays, 
we have come across several technological problems and 
difficulties which need be taken into consideration to 
achieve reliable results. These difficulties involve not only 
ghrelin and obestatin, but also other hypothalamic and 
gastrointestinal peptides. Until now, only ghrelin could 
be measured directly in plasma, with other peptides re-
quiring tedious and time-consuming extraction methods 
to remove interfering substances and to concentrate the 
peptides. Table I sets out the procedure needed to prepare 
obestatin or other peptide extracts from plasma. 
Plasma must be acidified with an equal amount of 1% 
trifluoroacetic acid (TFA) and the sample is centrifuged 
for 10,000 × g (18,000 rpm) for 20 minutes in a cooled 
ultracentrifuge (Beckman). The SEP-column containing 
200 mg of C-18 is activated by 3 ml of 60% acetonitrile in 
1% TFA and washed by 10 ml of 1% TFA. The acidified 
plasma is transferred to the column and the column is 
washed with 10 ml of 1% TFA and the eluate discarded. 
The retained obestatin is slowly eluted from the column 
by the addition of 3 ml of 60% acetonitrile in 1% TFA; 
this step takes three hours. The eluate is deeply frozen, 
freeze-dried overnight, and then stored at –70oC until 
use. Before radioimmunoassay, the samples are dis-
solved in 0.3 ml of the RIA buffer and are determined in 
duplicate. The preparation of obestatin extracts requires 
a laboratory with special equipment i.e.: ultracentrifuge, 
vacuum centrifuge, centrifuge with cooling system, 
freeze-dryer and SEP pack columns. To sum up, the 
procedure of preparing obestatin extracts is difficult, 
time-consuming and cumbersome. Each step is charged 
with some loss of isolated peptides, thus the efficiency of 
extraction varies from 65% to 85%; this could be control-
led by adding 125I obestatin to the plasma control sample 
and measuring its content in the final extract.
Furthermore, the assays procedure requires a proper 
room temperature in the laboratory, because a tempera-
ture higher than 24oC causes rapid peptide degradation 
and inactivation. Other methods of peptide measure-
ment are even more time-consuming and difficult, such 
as high pressure liquid chromatography with simultane-
ous mass spectrophotometry. 
The next difficulty to discuss is the marked instability 
of peptides, both in circulation and in plasma extracts, 
and the loss of their biological activity in the isolation 
process. The prolonged storage of ghrelin samples and 
obestatin extracts leads to peptide degradation. For this 
reason, the leaflets included RIA and ELISA kits contain 
recommendations to store the kits for no longer than 
one month at low temperatures. The manufacturer 
recommends using RIA kits as soon as possible after 
delivery, although laboratory staff tend to ignore this 
advice, and to use the kits right up to the end of the 
expiration date on the reagents.
Some peptides occur in two different forms: a bio-
logically active form and an inactive form. For instance, 
ghrelin occurs in an acylated, biologically active form, and 
in a desacylated inactive form. Antibodies included in 
Table I. Peptide extraction procedure from plasma 
Tabela I. Procedura ekstrakcji peptydów z osocza 
Collect blood into tubes containing EDTA and Trascloan to inhibit 
plasma proteolityc enzymes
Spin blood samples in cooled centrifuge and collect plasma
Acidify the plasma with concentrated HCl solution
Ultracentrifuge the samples at 10,000 × g for 20 minutes at 4∞C 
and discard the precipitate
To remove plasma proteins, perform liquid chromatography on 
activated C18 SEP column
Wash the column with 1% trifluoroacetic acid (TFA)
To elute the peptide retained on the column, add 60% acetonitrile 
in 1% TFA
Concentrate eluate on the Speed Vac centrifuge and freeze-dry 
overnight
Dissolve the eluate just before assay
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RIA kits contain polyclonal antibodies that measure total 
ghrelin and do not differentiate between the two forms.
Another difficulty is that certain peptide antibodies 
give cross-reactions with other peptides. Thus it is im-
portant to check the specificity of antibodies. Introduc-
ing monoclonal antibodies into the next generation of 
RIA kits will probably greatly enhance the specificity of 
the assays and allow the achievement of more consistent 
results from different laboratories.
There are as yet no international standards for 
biologically active peptides of the hypothalamus or 
gastrointestinal tract, probably because of the rapid 
degradation of these peptides. Therefore results ob-
tained in different laboratories vary greatly. Particular 
laboratories obtain different and probably divergent 
results even when the RIA kits used are from the same 
manufacturer. 
Table II presents varying results published by diffe-
rent authors. Some of them found a ghrelin concentra-
tion below 100 pg/ml [30, 31, 35]; this may result from 
improper handling of the reagents and inappropriate 
conditions of transportation, storage and laboratory 
procedures, that require temperatures below 24oC. 
In hot countries, air conditioning in laboratories is 
essential. Publications from some laboratories [25, 28, 
36] have reported surprisingly high ghrelin concentra-
tions, above 1,000 pg/ml. This phenomenon is difficult 
to explain, because the available ghrelin standard curve 
gives reliable results in the working range from 50 to 
1,000 pg/ml and the authors do not explain in these 
papers how they measured such high results. Even in 
laboratories of the highest scientific standards, such as 
Aarhus Hospital in Denmark, plasma ghrelin concentra-
tion in controls was 1,870 pg/ml in 2003 [25], whereas in 
2008 was 686 pg/ml [32].
At present, it is not possible to exactly define the 
normal plasma ghrelin and obestatin concentra-
tions. However, most scientific publications report 
a ghrelin concentration range of 150–600 pg/ml and this 
was what we found in our study.
 In some studies, the results of plasma ghrelin con-
centration using kits of Linco give results several times 
higher than results obtained using Phoenix kits [37, 
38]. In RIA kit packages, the declared concentration of 
ghrelin in the control sample given by the manufac-
turer greatly differs; for example, a control sample may 
contain 53 or 102 pg/ml of ghrelin; therefore in patient 
samples the ghrelin concentration could also be two 
times greater, or half the size. Including the samples 
of healthy control subjects would partially remove 
these obstacles encountered in commercial RIA kits 
and achieve more reliable results to each RIA run. This 
would allow an estimation of how the results obtained 
in patients differed statistically from the control group. 
An additional cause of laboratory error in ghrelin 
assays is the requirement to dissolve the ghrelin stock 
solution 10,000 times to get the highest point of the 
standard curve. This leads to unavoidable ghrelin loss 
by absorption on glass and plastic pipette tips. 
Conclusions
Only some hypothalamic or intestinal peptides cross the 
blood-brain barrier and are present in the circulation 
and thus eligible to assay.
The concentration of several peptides is extremely 
low. These peptides require laborious extraction proce-
dures and sophisticated laboratory equipment.
Hypothalamic and intestinal peptides are labile 
and prone to rapid degradation by blood and tissue 
enzymes. This requires the addition of enzymatic inhibi-
tors and the storage of the reagents at low temperature.
The occurrence of active and inactive forms of pep-
tides and their isoforms may give different results when 
using polyclonal antibodies contained in commercially 
available kits, which measure a total of peptide and do 
not differentiate between these forms.
A lack of international standards of several active 
peptides (including ghrelin and obestatin) and techno-
logical difficulties in the assays hinder direct compari-
Table II. Ghrelin concentrations reported by various authors 
Tabela II. Stężenia greliny podawane przez różnych autorów 
Plasma ghrelin concentration 
in controls [pg/ml]
Authors [ref no.]
514 ± 63 Otto et al. [21]
124 ± 11 Caminos et al. [22]
109 ± 24 DelParigi [23]
380.5 Bellone et al. [24]
1,870 ± 195 Riis et al. [25]
125 ± 110 Bergmann et al. [26]
264 ± 38 Morpurgo et al. [27]
3,127± 397 Rojdmark et al. [28]
561 ± 32.1 Gimenez-Palop et al. [29]
54.1 ± 35.5 Altinova et al. [30]
50.5 ± 34.8 Altinova et al. [31]
150.84 ± 75.87 Ruchała [18]
686 ± 53.7 Gjedde et al. [32]
275.5 ± 47.9 Kosowicz et al. [16]
985 ± 64.2 Xin et al. [33]
453 Tanaka et al. [34]
85 Malendowicz et al. [35]
2,345 Braclik et al. [36]
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sons of results originating from different scientific in-
stitutions. In each assay run, a control group of healthy 
subjects should be included to allow evaluation of how 
the patient’s results differ statistically from controls.
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